G. Schreier

Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project

A. Cañete, R. Ladenstein, V. Castel, 2018, Clinical and Translational Oncology.

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

M. Gaze, U. Pötschger, T. Trahair, 2020, Cancers.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ruth Ladenstein, Henrik Schroeder, Ulrike Pötschger, 2018, The Lancet. Oncology.

A Web-based platform for interdisciplinary biomedical research.

Ruth Ladenstein, Guenter Schreier, Juergen Messmer, 2009, Frontiers in bioscience.

Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).

I. Yaniv, M. Popovic, G. C. Chan, 2016 .